Inactive Instrument

Bruker Cellular Analysis, Inc.

Equities

BLI

US0843101017

Biotechnology & Medical Research

Bruker Cellular Analysis : Phenomenex Introduces Biozen dSEC-7, A New Way to Study AAVs with Unprecedented Speed and Efficiency

March 03, 2024 at 08:26 pm EST

For security purposes

FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.

Attachments

Original Link
Permalink

Disclaimer

Phenomex Inc. published this content on 04 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2024 01:26:04 UTC.

Latest news about Bruker Cellular Analysis, Inc.

PhenomeX Inc Announces Board Changes	23-10-02	CI
PhenomeX Inc. has Changed its Name to Bruker Cellular Analysis, Inc	23-10-02	CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from NASDAQ Composite Index	23-10-02	CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from S&P TMI Index	23-10-02	CI
Bruker Corporation completed the acquisition of PhenomeX Inc..	23-09-28	CI
Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform	23-09-27	CI
PhenomeX Inc. Announces the Release of SpotLight? Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows	23-09-21	CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from S&P Global BMI Index	23-09-18	CI
Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark? Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics	23-09-15	CI
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
TD Cowen Downgrades PhenomeX to Market Perform From Outperform, Price Target is $1	23-08-23	MT
North American Morning Briefing : Nvidia Results -2-	23-08-23	DJ
Berenberg Downgrades PhenomeX to Hold From Buy, Adjusts Price Target to $1 From $8	23-08-22	MT
North American Morning Briefing : Focus Shifts to -2-	23-08-21	DJ
Morgan Stanley Upgrades PhenomeX to Equalweight From Underweight, Adjusts Price Target to $1 From $5	23-08-18	MT
Bruker to Acquire PhenomeX in $108 Million All-Cash Deal	23-08-17	MT
Bruker Corp & Phenomex Inc Announce Agreement For Bruker To Acquire Phenomex In All-Cash Transaction	23-08-17	RE
Bruker Corporation signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc..	23-08-16	CI
Berenberg Bank Adjusts PhenomeX Price Target to $8 From $9, Maintains Buy Rating	23-08-15	MT
Earnings Flash (CELL) PHENOMEX Posts Q2 Revenue $14.1M, vs. Street Est of $17.4M	23-08-14	MT
Earnings Flash (CELL) PHENOMEX Posts Q2 Revenue $14.1M, vs. Street Est of $17.4M	23-08-14	MT
PhenomeX Inc. Announces Impairment of Goodwill for the Second Quarter Ended June 30, 2023	23-08-14	CI
PhenomeX Inc. Reiterates Earning Guidance for the Full Year of 2023	23-08-14	CI
PhenomeX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Phenomex Board Launches A Process to Explore, Review, Evaluate A Range of Potential Strategic Alternatives	23-07-07	CI

Chart Bruker Cellular Analysis, Inc.

Duration

Period

More charts

Company Profile

PhenomeX Inc., formerly Berkeley Lights, Inc., is a functional cell biology company. The Company enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The Company enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company's platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research